Keywords:
CRISPR gene editing; Cardiac disease modelling; Congenital heart disease; GATA4; Induced pluripotent stem cells
Abstract:
Patients with congenital heart disease (CHD) are identified in 1% of live births. Improved surgical intervention means many patients now survive to adulthood, the corollary of which is increased mortality in the over-65-year-old congenital heart disease population. In the clinic, genetic sequencing increasingly identifies novel genetic variants in genes related to CHD.